메뉴 건너뛰기




Volumn 22, Issue 2, 2003, Pages 147-154

In vitro susceptibility of 4903 bacterial isolates to gemifloxacin - An advanced fluoroquinolone

Author keywords

Fluoroquinolone; Gemifloxacin; Streptococcus pneumoniae

Indexed keywords

BETA LACTAMASE; CIPROFLOXACIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; METICILLIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

EID: 0042591063     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00092-X     Document Type: Article
Times cited : (19)

References (16)
  • 1
    • 0033963629 scopus 로고    scopus 로고
    • A review of clinical trials with fluoroquinolones with an emphasis on new agents
    • Blondeau J.M. A review of clinical trials with fluoroquinolones with an emphasis on new agents. Expert Opin. Investig. Drugs. 9:2000;383-413.
    • (2000) Expert Opin. Investig. Drugs , vol.9 , pp. 383-413
    • Blondeau, J.M.1
  • 3
    • 0034087347 scopus 로고    scopus 로고
    • In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA
    • McCloskey L., Moore T., Niconovich N., et al. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. J. Antimicrob. Chemother. 45:2000;13-21.
    • (2000) J. Antimicrob. Chemother. , vol.45 , pp. 13-21
    • McCloskey, L.1    Moore, T.2    Niconovich, N.3
  • 4
    • 0034534006 scopus 로고    scopus 로고
    • In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers and assessment of disk diffusion test interpretive criteria
    • Fuchs P.C., Barry A.L., Brown S.D. In vitro activity of gemifloxacin against contemporary clinical bacterial isolates from eleven North American medical centers and assessment of disk diffusion test interpretive criteria. Diag. Microbiol. Infect. Dis. 38:2000;243-253.
    • (2000) Diag. Microbiol. Infect. Dis. , vol.38 , pp. 243-253
    • Fuchs, P.C.1    Barry, A.L.2    Brown, S.D.3
  • 5
    • 0008328298 scopus 로고    scopus 로고
    • In vitro susceptibility of 4768 bacterial isolates to gemifloxacin - An advanced fluoroquinolone
    • Toronto, ON, Canada, September 17-20, American Society of Microbiology, Washington, DC. Abstract E2309
    • Blondeau JM, Borsos S. In vitro susceptibility of 4768 bacterial isolates to gemifloxacin - an advanced fluoroquinolone, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, ON, Canada, September 17-20, 2000. American Society of Microbiology, Washington, DC. Abstract E2309.
    • (2000) 40th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • Blondeau, J.M.1    Borsos, S.2
  • 6
    • 0033595136 scopus 로고    scopus 로고
    • Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
    • Chen D.K., McGeer A., De Azavedo J., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N. Engl. J. Med. 341:1999;233-239.
    • (1999) N. Engl. J. Med. , vol.341 , pp. 233-239
    • Chen, D.K.1    McGeer, A.2    De Azavedo, J.3    Low, D.E.4
  • 7
    • 0036233721 scopus 로고    scopus 로고
    • Activities of new fluoroquinolones, ketolides and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000
    • Gershon A.S., De Azavedo J., McGeer A., et al. Activities of new fluoroquinolones, ketolides and other antimicrobials against blood culture isolates of viridans group streptococci from across Canada, 2000. Antimicrob. Agents Chemother. 46:2002;1553-1556.
    • (2002) Antimicrob. Agents Chemother. , vol.46 , pp. 1553-1556
    • Gershon, A.S.1    De Azavedo, J.2    McGeer, A.3
  • 8
    • 0036242204 scopus 로고    scopus 로고
    • Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000
    • Low D.E., De Azavedo J., Weiss K., et al. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob. Agents Chemother. 46:2002;1295-1301.
    • (2002) Antimicrob. Agents Chemother. , vol.46 , pp. 1295-1301
    • Low, D.E.1    De Azavedo, J.2    Weiss, K.3
  • 9
    • 0034989717 scopus 로고    scopus 로고
    • Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents
    • Blondeau J.M., Vaughan D., Laskowski R., Borsos S. Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents. Int. J. Antimicrobial. Agents. 17:2001;457-464.
    • (2001) Int. J. Antimicrobial. Agents , vol.17 , pp. 457-464
    • Blondeau, J.M.1    Vaughan, D.2    Laskowski, R.3    Borsos, S.4
  • 10
    • 0034053256 scopus 로고    scopus 로고
    • Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms
    • Blondeau J.M., Laskowski R., Bjarnason J., Stewart C. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int. J. Antimicrobial. Agents. 14:2000;45-50.
    • (2000) Int. J. Antimicrobial. Agents , vol.14 , pp. 45-50
    • Blondeau, J.M.1    Laskowski, R.2    Bjarnason, J.3    Stewart, C.4
  • 11
    • 0033751574 scopus 로고    scopus 로고
    • A comparative in vitro surveillance study of gemifloxacin activities against 2632 recent Streptococcus pneumoniae isolates from across Europe, North America and South America
    • Hoban D.J., Bouchillon S.K., Karlowsky J.A., et al. A comparative in vitro surveillance study of gemifloxacin activities against 2632 recent Streptococcus pneumoniae isolates from across Europe, North America and South America. Antimicrob. Agents Chemother. 44:2000;3008-3011.
    • (2000) Antimicrob. Agents Chemother. , vol.44 , pp. 3008-3011
    • Hoban, D.J.1    Bouchillon, S.K.2    Karlowsky, J.A.3
  • 12
    • 0033734978 scopus 로고    scopus 로고
    • Activities of clinafloxacin, gatifloxacin, gemifloxacin and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae
    • Jorgensen J.H., Weigel L.M., Swenson J.M., Whitney C.G., Ferraro M.J., Tenover F.C. Activities of clinafloxacin, gatifloxacin, gemifloxacin and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:2000;2962-2968.
    • (2000) Antimicrob. Agents Chemother. , vol.44 , pp. 2962-2968
    • Jorgensen, J.H.1    Weigel, L.M.2    Swenson, J.M.3    Whitney, C.G.4    Ferraro, M.J.5    Tenover, F.C.6
  • 13
    • 0035873488 scopus 로고    scopus 로고
    • Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999
    • Hoban D.J., Doern G.V., Fluit A.C., Roussel-Delvallez M., Jones R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32:2001;S81-S93.
    • (2001) Clin. Infect. Dis. , vol.32
    • Hoban, D.J.1    Doern, G.V.2    Fluit, A.C.3    Roussel-Delvallez, M.4    Jones, R.N.5
  • 14
    • 0035139520 scopus 로고    scopus 로고
    • Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae
    • Blondeau J.M., Zhao X., Hansen G., Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 45:(15):2001;433-438.
    • (2001) Antimicrob Agents Chemother , vol.45 , Issue.15 , pp. 433-438
    • Blondeau, J.M.1    Zhao, X.2    Hansen, G.3    Drlica, K.4
  • 15
    • 0012633187 scopus 로고    scopus 로고
    • Comparison of gatifloxacin (GA), gemifloxacin (GM), levofloxacin (L) and moxifloxacin (M) by the mutation prevention concentration (MPC) using 160 clinical isolates of Streptococcus pneumoniae (SP)
    • Chicago, IL, September 20-22, American Society of Microbiology, Washington, DC. Abstract #76
    • Blondeau JM, Hansen G, Zhao X, Drlica K. Comparison of gatifloxacin (GA), gemifloxacin (GM), levofloxacin (L) and moxifloxacin (M) by the mutation prevention concentration (MPC) using 160 clinical isolates of Streptococcus pneumoniae (SP). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 20-22, 2001. American Society of Microbiology, Washington, DC. Abstract #76.
    • (2001) 40th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • Blondeau, J.M.1    Hansen, G.2    Zhao, X.3    Drlica, K.4
  • 16
    • 0037229075 scopus 로고    scopus 로고
    • Mutant prevention concentration of gemifloxicin for clinical isolates of Streptococcus pneumoniae
    • Hansen G., Drlica K., Blondeau J.M. Mutant prevention concentration of gemifloxicin for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 47:(1):2003;440-441.
    • (2003) Antimicrob Agents Chemother , vol.47 , Issue.1 , pp. 440-441
    • Hansen, G.1    Drlica, K.2    Blondeau, J.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.